Skip to main content

Table 1 Baseline Characteristics of the Patients (N = 60)

From: Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study

Demographic profile: Liraglutide, N = 30 Dulaglutide, N = 30 P value
Male, n (%) 28(46.7%) 13 (43.3%) 15 (50%) 0.605
Female, n (%) 32 (53.3%) 17 (56.7%) 15 (50%)  
Age(years), Mean ± SEM 47.75 ± 1.22 47.33 ± 1.91 48.17 ± 1.55 0.736
Height (centimeters), Mean ± SEM 161.53 ± 1.2 159.97 ± 1.52 163.10 ± 1.83 0.193
Body weight(Kg), Mean ± SEM 88.3 ± 1.68 89.43 ± 2.60 87.17 ± 2.16 0.506
Diabetes duration, (years), Mean ± SEM 6.07 ± 0.70 5.55 ± 0.94 6.59 ± 1.03 0.46
SBP(mmHg), Mean ± SEM 136.07 ± 1.84 137.83 ± 2.50 134.30 ± 2.71 0.342
DBP(mmHg), Mean ± SEM 82.1 ± 1.15 83.47 ± 1.58 80.73 ± 1.64 0.236
BMI(kg/m2), Mean ± SEM 34.99 ± 5.66 34.92 ± 0.86 32.84 ± 0.77 0.078
BMI – 25 -29.9 10 (16.67%)    
BMI - 30-34.9 30 (50%)    
BMI - 35-39.9 12 (20%)    
BMI - ≥40 8 (13.33%)    
FPG(mg/dL), Mean ± SEM 167.83 ± 7.04 160.13 ± 8.17 175.53 ± 11.45 0.278
HbA1c(%), Mean ± SEM 8.46 ± 0.17 8.49 ± 0.26 8.43 ± 0.21 0.847
On Metformin, n (%) 60 (100%) 30 (100%) 30 (100%) 1.00
On SGLT-2is, n (%) 60 (100%) 30 (100%) 30 (100%) 1.00